{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T11:04:04Z","timestamp":1790420644105,"version":"4.1.0"},"reference-count":63,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T00:00:00Z","timestamp":1311811200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chirality"],"published-print":{"date-parts":[[2011,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The structural and conformational features of the potent 10\u2010membered enediyne\u2010containing calicheamicin \u03b3<jats:inline-graphic xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"graphic\/tex2gif-stack-2.gif\" xlink:title=\"urn:x-wiley:08990042:media:CHIR20990:tex2gif-stack-2\"\/> that account for its remarkable DNA site\u2010specific binding and cleavage are reviewed. A variety of spectroscopic and biophysical techniques were used to gain insight into the binding and stereospecific DNA cleavage of this potent antitumor agent. These include gel\u2010shift cleavage assays, atom transfer NMR experiments, drug\u2010DNA conformational studies, circular dichroism, and capillary electrophoresis. Computational descriptions are described for the DNA binding and cleavage of calicheamicin and its activated transient intermediates based on density functional and molecular mechanics calculations. In addition, the structure and clinical utility of calicheamicin immunoconjugates for antibody\u2010targeted chemotherapy is presented. Chirality, 2011. \u00a9 2011 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/chir.20990","type":"journal-article","created":{"date-parts":[[2011,7,28]],"date-time":"2011-07-28T14:02:21Z","timestamp":1311861741000},"page":"660-671","source":"Crossref","is-referenced-by-count":30,"title":["Structural and conformational features relevant to the anti\u2010tumor activity of calicheamicin \u03b3"],"prefix":"10.1002","volume":"23","author":[{"given":"George A.","family":"Ellestad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,7,28]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00245a050"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00245a051"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00029a030"},{"key":"e_1_2_9_5_2","first-page":"1070","volume":"42","author":"Lee MD","year":"1989","journal-title":"Calicheamicins, a novel family of antitumor antibiotics. 3. Isolation, purification and characterization of calicheamicins \u03b21Br, \u03b31Br, \u03b12I, \u03b13I, \u03b21I, \u03b31I, and \u03b41I. J Antibiot"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(01)80810-8"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00245a048"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00245a049"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1021\/jm9600398"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja961122n"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja0296780"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1021\/ar50061a004"},{"key":"e_1_2_9_13_2","first-page":"609","volume-title":"Small molecule DNA and RNA binders: from synthesis to nucleic acid complexes","author":"Cosgrove JP","year":"2003"},{"key":"e_1_2_9_14_2","first-page":"29","volume-title":"Antibiotics as antitumor agents","author":"Fantini A","year":"1995"},{"key":"e_1_2_9_15_2","first-page":"17","volume-title":"Antibiotics as antitumor agents","author":"Greenstein M","year":"1995"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00065a013"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.3240341"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.2717946"},{"key":"e_1_2_9_19_2","first-page":"327","volume-title":"Antibiotics as antitumor agents","author":"Goldberg I","year":"1995"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00182a053"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00049a069"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00071a004"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00088a005"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.92.23.10506"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1006\/jmbi.1996.0718"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja0005183"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.88.17.7464"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00088a006"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4020(01)80622-0"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00136a004"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/chem.200700504"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00003a035"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1021\/ol0494919"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2005.04.007"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4039(00)93571-8"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00034a068"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1039\/b001204l"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00068a020"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00017a038"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.4.1105"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.19.10643"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.10.4608"},{"key":"e_1_2_9_43_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja000519v"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00012a070"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00087a005"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00173a058"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja953162h"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/0968-0896(95)00054-K"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00012a005"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0040-4020(01)80624-4"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi992227g"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-349-09871-2_1"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1021\/ja00167a069"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.199614781"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc010021y"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210364"},{"key":"e_1_2_9_57_2","first-page":"103","volume-title":"The genesis of the antibody conjugate gemtuzumab ozogamicin (Mylotarg) for acute myeloid leukemia. RSC Drug Discovery Series, 4 (Accounts in drug discovery)","author":"Hamann RR","year":"2011"},{"key":"e_1_2_9_58_2","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.cbpa.2010.06.170","article-title":"Antibody\u2010drug conjugates: targeted drug delivery for cancer","volume":"14","author":"Alley SC","journal-title":"Curr Opin Chem Biol"},{"key":"e_1_2_9_59_2","first-page":"224","volume-title":"Antibody\u2010drug conjugates in oncology. RSC Drug Discovery Series, 5 (New frontiers in chemical biology)","author":"Hamann PR","year":"2011"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-006-0260-5"},{"key":"e_1_2_9_61_2","first-page":"2925","article-title":"Targeted therapy with a novel enediyne antibiotic calicheamicin \u03b81\n                  I effectively suppresses growth and dissemination of liver mtastases in a syngeneic model of murine neuroblastoma","volume":"58","author":"Lode HN","year":"1998","journal-title":"Cancer Res"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc900128h"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/anie.199401831"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.20.9203"}],"container-title":["Chirality"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fchir.20990","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/chir.20990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T17:48:50Z","timestamp":1696960130000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/chir.20990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,7,28]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["10.1002\/chir.20990"],"URL":"https:\/\/doi.org\/10.1002\/chir.20990","archive":["Portico"],"relation":{},"ISSN":["0899-0042","1520-636X"],"issn-type":[{"value":"0899-0042","type":"print"},{"value":"1520-636X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,7,28]]}}}